Cassava Sciences (FLNA) Stock Price, News & Analysis

Company Overview

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on simufilam, an investigational oral therapy designed to target an altered form of the scaffolding protein filamin A that Cassava has linked to Alzheimer’s disease pathology.

Simufilam has been evaluated in clinical studies involving patients with Alzheimer’s disease, but it is an investigational product and is not approved for commercial use. Cassava Sciences has not marketed any approved products and has primarily operated as a research and development company serving the pharmaceutical and biotechnology markets.

Founded in 1998 as Pain Therapeutics, the company adopted the name Cassava Sciences in 2018. It is headquartered in Austin, Texas, and was founded by Remi Barbier, who has served as its chief executive officer. Cassava Sciences is generally associated with the Nasdaq ticker SAVA; the ticker FLNA does not appear to correspond to the company.

Key Stats

• Today's Range: $0.72 to $0.89
• 50-Day Range: $0.68 to $1.03
• 52-Week Range: $0.67 to $4.98
• Volume: 2.05 million shs
• Average Volume: 1.02 million shs
• Market Capitalization: $41.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

Cassava Sciences Stock Analysis - MarketRank™

Cassava Sciences scored higher than 37% of companies evaluated by MarketBeat, and ranked 715th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cassava Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Cassava Sciences has a consensus price target of $5.00, representing about 486.0% upside from its current price of $0.85.

Amount of Analyst Coverage

Cassava Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cassava Sciences is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cassava Sciences is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cassava Sciences has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.49% of the float of Cassava Sciences has been sold short.

Short Interest Ratio / Days to Cover

Cassava Sciences has a short interest ratio ("days to cover") of 18.69, which indicates bearish sentiment.

Change versus previous month

Short interest in Cassava Sciences has recently decreased by 1.19%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cassava Sciences does not currently pay a dividend.

Dividend Growth

Cassava Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.59

News Sentiment

Cassava Sciences has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Cassava Sciences this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for FLNA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

5 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cassava Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.60% of the stock of Cassava Sciences is held by insiders.

Percentage Held by Institutions

38.05% of the stock of Cassava Sciences is held by institutions.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 9/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:FLNA
• Previous Symbol: NASDAQ:SAVA
• CIK: 1069530
• Web: cassavasciences.com
• Phone: 512-501-2444
• Fax: 512-501-0414
• Employees: 30
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Cassava Sciences: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +488.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$90.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -58.78%
• Return on Assets: -36.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.08
• Quick Ratio: 2.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.54 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 48,310,000
• Free Float: 46,086,000
• Market Cap: $41.06 million
• Optionable: Optionable
• Beta: -0.69